Abstract:Cardiac resynchronization therapy (CRT) is now an established therapy for patients with advanced heart failure with electromechanical delay, although nonresponders have been observed. Because natriuretic peptides are relevant markers to reflect the severity of heart failure and filling pressure of cardiac chambers, it may be helpful to assess the efficacy of CRT.Forty-two patients with heart failure with QRS of >120 msec were recruited; their serial N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were measured at baseline and at 1 and 3 months after CRT. There was a reduction in NT-proBNP level 1 month after CRT (2655 +/- 2242 pg/mL vs 2149 +/- 2033 pg/mL; P = .03), which was further reduced at 3 months (1473 +/- 1786 pg/mL; P < .001 vs baseline). The reduction of NT-proBNP correlated with the change of left ventricular (LV) end-systolic volume (r = 0.53; P = .001) or LV ejection fraction ( r = -0.49; P = .002) and with improvement in exercise capacity after CRT for 3 months (r = 0.50; P = .002). The patients were classified by the degree of reduction in NT-proBNP as group 1 (reduction of > or =50% vs baseline; n = 19) and group 2 (reduction of <50% vs baseline; n = 23). The degree of LV reverse remodeling (-31.8 +/- 24.7 mL vs -12.6 +/- 19.2 mL; P = .007) and gain in LV ejection fraction (+12.5% +/- 8.8% vs +4.6% +/- 5.8%; P = .002) were significantly better in group 1 than group 2. Both the all-cause mortality rate (Log-rank chi 2 = 4.01; P = .04) and the composite end-point of mortality rate or hospitalization rate for cardiovascular causes (Log-rank chi 2 = 4.31; P = .02) were significantly lower in group 1 than in group 2.Serial monitoring of NT-proBNP may be helpful to predict a favorable outcome after CRT. Those who had a reduction of NT-proBNP level of >/=50% were more likely to exhibit a favorable response.

Serum Levels of N-terminal Pro-Brain Natriuretic Peptide and Matrix Metalloproteinase-9 in Patients with Chronic Heart Failure Before and after Cardiac Resynchronization Therapy

The dynamic of serum N-terminal pro-brain natriuretic peptide and troponin T in pre- and post-cardiac resynchronization therapy

Clinical Effect of Cardiac Resynchronization Therapy in Patients with Chronic Heart Failure

The change of plasma N-terminal brain natriuretic peptide(BNP) level in the heartt failure patients after cardiac resynchronization therapy

Improvement of serum NT-ProBNP predicts improvement in cardiac function and favorable prognosis after cardiac resynchronization therapy for heart failure.

Effects of cardiac resynchronization therapy on serum concentration of P-Ⅰ NP,P-Ⅲ CP and Ⅳ-C

N-terminal Pro-Brain Natriuretic Peptide in Predicting Early Clinical Response to Cardiac Resynchronization Therapy in Patients with Heart Failure

[Factors Associated with the Efficacy of Cardiac Resynchronization Therapy in Patients with Chronic Heart Failure].

Clinical Observation of Resynchronization Therapy for Patients with Chronic Heart Failure

N-Terminal Probrain Natriuretic Peptide and Matrix MetaIloproteinase-9 in Early Ventricular Remodeling of Non-ST Elevation Acute Coronary Syndrome

Changes and clinical significance of serum matrix metalloproteinase-9 in patients with congestive heart failure

Clinical effect of resynchronization therapy in patients with chronic heart failure

Change of Plasma ADAMTs-1 and MMPs Levels in Patients with Coronary Heart Disease Complicated with Chronic Heart Failure and Its Significance

Long-term effects of cardiac resynchronization therapy in patients with congestive heart failure

Long term therapeutic effect of cardiac resynchronization therapy on patients with congestive heart failure

Effectiveness of Carvedilol on Serum Hs-Crp, NT-proBNP, MMP-9 and Cardiac Function in Patients with Chronic Heart Failure

Effect of cardiac resynchronization therapy on right ventricular systolic function in patients with chronic heart failure

Novel Heart Failure Biomarkers Predict Improvement of Mitral Regurgitation in Patients Receiving Cardiac Resynchronization Therapy-The BIOCRT Study.

Effect of serum creatinine on efficacy and prognosis of cardiac resynchronization therapy

Changes of Serum Matrix Metalloproteinase-3 and Their Clinical Significance in Patients with Congestive Heart Failure

Efficacy of cardiac resynchronization therapy in chronic heart failure patients with persistent atrial fibrillation